Subject Index

A
Acetoacetate, 8, 32
Acetoacetyl-CoA thiolase, 99
Acetyl amino acid, physiological significance, 166
Acetyl-CoA, 8
liver, routes of disposal, 21
N-Acetylaspartic acid, 163
N-Acetylaspartic aciduria, 101–102
Activation, fatty acid, 1–3
Acyl-CoA dehydrogenase, 4
Acyl-CoA intermediate, 14
Acyl-CoA oxidase, 30–31, 48
fatty acyl-CoA ester, 15
trihydroxycoprostanoyl-CoA, 15
trihydroxycoprostanoyl-CoA oxidase, 15
Acylcarnitine, 24, 28
liver, 63
m/z 99 fragment, 60
plasma, 27–28, 61–63
tissue samples, 63
triple quadrupole, 58–60
Acylcoenzyme A dehydrogenase deficiency, sudden infant death syndrome, 72
Adenosine deaminase transfer, 280
Adrenaline, 165
inborn error biochemical characteristics, 49
inborn error diagnosis, 49
Adreno-testiculo-leuko-myeloneuropathic complex, 46–47
Adrenoleucodystrophy, displacement bone marrow transplantation, 238
Alcoholic cirrhosis, glycerol-3-phosphate, 106
Aldolase B, 183–185
decreased activity, 187
hereditary fructose intolerance, 185
Alpha-oxidation
brain, 16
liver, 16
phytanic acid, 10–12, 16
Amino acid
catabolism defects, 93
competitive inhibition, 134
placental transport, 125–126
Aminoaciduria, dibasic, 113
alpha-1-Antitrypsin deficiency emphysema, 262
liver transplantation, 213–216, 265–266, 269
albuminuria, 220
clinical features, 213–214
fulminating form, 220
hematuria, 220
pathogenesis, 214
results, 215–216
Arginine-succinate deficiency, modified Murphy test, 122
Arginine, 122
Argininosuccinic aciduria, 123
Asialoglycoprotein receptor, 281
Aspartoacylase deficiency, 163
biochemical defect, 163
clinical picture, 163
treatment, 163
Autosomal recessive helper T-cell defect, displacement bone marrow transplantation, 229

B
Bare lymphocyte syndrome, displacement bone marrow transplantation, 229
Benzoyl carnitine, 124
Beta-oxidation
bile acid intermediate, 1
carboxy side chain, 1
Beta-oxidation (contd.)
castor bean endosperm, 1
eicosanoid, 1
fatty acid, 1
hexadecanolate, 20–21
linoleoyl-CoA, 7
long chain dicarboxylic fatty acid, 1
long chain fatty acid, 1
medium chain dicarboxylic fatty acid, 1
medium chain fatty acid, 1
mitochondria, 1, 3–8, 4–5
  blood platelets, 36–37
  control, 20–21
  episodic hypoglycemia, 19
  flavoprotein-linked dehydrogenation, 19
  hydration, 19
  inherited disorders, 19–34
  leukocytes, 36–37
  lipid storage myopathy, 19
  NAD⁺-linked dehydrogenation, 19
  radiochemical measurement, 37
  radiolabeled fatty acid, 37
  rate of recycling of CoA, 20–21
  redox state, 20–21
  Reye’s syndrome, 19
  role, 9–10
  saturated acyl-CoA ester, 19
  suberylglycinuria, 19
  thiolysis, 19
oleyl-CoA, 7
peroxisome, 1, 3–8, 4–5, 8
  chain-shortening system, 8
  dihydroxycholestanolic acid, 44
  disorders, 43–51
  inborn errors, 44–49
  pathogenic aspects, 50–51
  peroxisome deficiency disorder, 44–46
  plant, 16
  prenatal diagnosis, 50
  role, 9–10
  treatment, 51
  trihydroxycholestanolic acid, 44
  unidentified disorders, 48–49
  very long chain fatty acids, 43–44
  plant, 16
prostaglandin, 1, 10
  reactions, 3–4
  short chain fatty acid, 1
  very long chain fatty acid, 1
xenobiotic, 1
Bifunctional protein, 6, 53
Bifunctional protein deficiency, 48
Bile acid intermediate, beta-oxidation, 1
Bile salt stimulated lipase, 91
Biliary atresia, glycerol-3-phosphate, 106
Bilirubin, 221
  galactosemia, 180
Biopterin deficiency, 165
Biotinidase deficiency, displacement
  bone marrow transplantation, 236
Blood-brain barrier, development, 134
Bone marrow, gene therapy, 276
Bone marrow transplant, 106
galactosemia, 179
Bovine pancreatin, 133
Brain, alpha-oxidation, 16
Branched-chain 2-oxo acid dehydrogenase, 137
  maple syrup urine disease, 140–141
Branched-chain amino acid, metabolic pathways, 137–140
Branched-chain amino acid inborn metabolic error, 137–149
Breast milk jaundice, 91
Butyrate, 9
Byler disease, liver transplantation, 268–269, 270

C
C10, carnitine, 91
C12 intermediate, 14
C14 intermediate, 14
C16 intermediate, 14
C26 level, 53–54
Canavan’s spongiform leukodystrophy, 101–102, 163
Caproic acid, 81
Carbamyl glutamate, 122
Carbohydrate, catabolism defects, 93
Carbohydrate transfer, intestinal mucosa, 197–202
Carboxy side chain, beta-oxidation, 1
Carnitine, 12–13
  beta-ketothalase deficiency, 68
  branched chain disorder, 68
  C10, 91
cardiomyopathy, 69
  as diagnostic tool, 57–63
fast atom bombardment-mass spectrometry, 57–63, 66
glutaric aciduria type I, 69–70
hyperammonemia, 117
isovaleric acidemia, 63–66
3-ketothiolase deficiency, 64–66
medium chain CoA dehydrogenase, 64–66
methylmalonic aciduria, 63–66
multiple acyl-CoA dehydrogenase deficiency, 64–66
myogenic hypotonia, 68–69
normal levels, 68
organic acidemia, urinary excretion, 104
plasma, 27–28
propionic acidemia, 63–66
sudden infant death syndrome, 78
toxicity, 70
triple quadrupole, 58–60
uptake, 69
urea cycle inborn error, 117
Carnitine deficiency
medium chain CoA dehydrogenase deficiency, 58
primary, 41
Carrier detection
hyperammonemia, 120
urea cycle inborn error, 120
Catecholamine, 165
Cerebro-hepato-renal syndrome of Zellweger, 45
Cerebrospinal fluid, glycine, 156
Ceruloplasmin, Wilson’s disease, 221
Cholesterol
degradation, 10, 11
liver, 10, 11
Cholesterol biosynthesis, inherited disorder, 97
Cholesterol metabolism, 16–17, 97
Cholesterol synthesis, 3-methylglutaconic aciduria, 107
Chromosome 13, 216
Cis double bond, 6
Citrate, 8, 122
Clofibrate, 15
Conjugated glutarate, 107
Crigler-Najjar syndrome, liver transplantation
bilirubin, 221
brain damage, 221
heme synthesis inhibitor, 221
Crigler-Najjar syndrome type 1, liver transplantation, 267, 269, 273–274
incidence, 257
long-term effects, 257
natural history, 257
transplantation candidates, 257
Crotonase, 4
Cyclosporin A, 225–227, 246
Cystic fibrosis
gene therapy, 278
liver transplantation, 219
Cystinosis, liver transplantation, 262
Cytomegalovirus, displacement bone marrow transplantation, 247
Cytosol, long chain acyl-CoA synthetase, 23

D
Dehydration, 153
Dibasic aminoaciduria, 113
Dicarboxylic acid, 24, 28, 39
Dicarboxylic fatty acid oxidation mitochondria, 9
peroxisome, 9
Dienoyl-CoA isomerase, 17
Dienoyl-CoA reductase, 6, 17
Reye’s syndrome, 17
Dienoyl-CoA reductase/isomerase pathway, 6
Diethyl ether, organic aciduria, 94
Disorder of peroxisome biogenesis, 44–49
Displacement bone marrow transplantation, 223–241
adrenoleukodystrophy, 238
animal research value, 245
autosomal recessive helper T-cell defect, 229
bare lymphocyte syndrome, 229
biotinidase deficiency, 236
cytomegalovirus, 247
Fabry’s disease, 235
Fanconi’s syndrome, 236
Farber’s lipogranulomatosis, 239
fucosidosis, 236
future developments, 239–240
Gaucher’s disease, 234–235
Genetic anemia, 230–231
GM1 gangliosidosis, 238
Hunter’s disease, 237
Hurler’s disease, 232–233, 246
I-cell disease, 238
immunophylaxis, 225–227
inborn error categories, 244–245
Krabbe’s disease, 239
Lesch-Nyhan syndrome, 238
Maroteaux Lamy syndrome, 237
metachromatic leukodystrophy, 235
Morquio’s disease, 237
mucopolysaccharidosis, 232
Niemann-Pick disease, 236, 238–239
non-sex-linked severe combined immune deficiency, 228
nonfunctional lymphocyte, 229–230
osteopetrosis, 231–232
phagocyte error, 230
Pompe’s disease, 238
Refsom’s disease, 235
reticular dysgenesis, 228
San Filippo A disease, 237
San Filippo B disease, 233–234
severe combined immune deficiency, 228
cartilage hair dysplasia, 228
T-cell deficiency, 229
thalassemia, 247
treatable diseases, 225
Wiskott-Aldrich syndrome, 229
Wolman’s disease, 236, 246
Dopa-responsive hereditary progressive dystonia, 162
Dopamine therapy, 167
Duchenne muscular dystrophy, gene therapy, 278, 280
Dystrophin gene, gene therapy, 278

E
Eicosanoid, beta-oxidation, 1
Electron-transferring flavoprotein, 4
Emphysema, alpha-1-antitrypsin deficiency, 262
Endoplasmic reticulum, 3
Endothelial cell, 207–208
Enoyl-CoA hydrolase, 4
Enzyme replacement therapy, 133–134
Erucate, 51
Ethyl acetate, organic aciduria, 94
Exchange transfusion, hyperammonemia, 121–122
Extracellular matrix component, 208

F
Fabry’s disease, displacement bone marrow transplantation, 235
Familial hypercholesterolemia, liver transplantation, 257, 270
Fanconi’s syndrome, displacement bone marrow transplantation, 236
Farber’s lipogranulomatosis, displacement bone marrow transplantation, 239
Fast atom bombardment-mass spectrometry, carnitine, 57–63, 66
Fasting
15-hour, 78
fatty acid, 21
lipolysis, 21
pathogenic urinary metabolite, 22
sudden infant death syndrome, 72
Fasting provocation test, 37–38
safety, 37–38
Fat storage, 208
Fatty acid
activation, 1–3
beta-oxidation, 1
CoA thioester, 1
fasting, 21
mitochondria, 1–3
peroxisome, 1–3
Fatty acid oxidation, 1–13
secondary impairment, 32, 33
Fatty acyl-CoA ester, acyl-CoA oxidase, 15
Fetus, phenylketonuria, 126–127, 126–129
amino acid supplementation, 128
amino transport, 128
brain development, 127
damage mechanisms, 127–129
dopamine, 128
phenylalanine, 127
serotonin, 128
Fibroblast, glutaric acid, 107
Finnigan-MAT TSQ 70 tandem mass spectrometer, 68
Flavoprotein-linked dehydrogenation, 19
Floppy baby, sudden infant death syndrome, 75, 76
Free fatty acid, ketone body, 32
Fructokinase, 183–185
| Fructose                                       | clinical aspects, 169–171, 180 |
|                                              | diagnosis, 176, 180            |
| hepatocellular insufficiency, 195             | international prospective study, 178 |
| hyperuricemia, 188                           | legumes, 175                  |
| hyperuricosuria, 188                         | liver transplantation, 256    |
| infant, 193                                   | long-term outcome, 169–171    |
| intestinal mucosa                            | milk, 175                     |
| absorption, 199                               | neurological degeneration, 171|
| malabsorption, 199                            | pathogenesis, 173–174         |
| natural sources, 190                         | pseudotumor cerebri, 171     |
| phosphorylated, 204                           | pulses, 175                   |
| self imposed restrictions, 190–191, 193      | treatment, 175                |
| small intestine, 197–199                      | Gamma-aminobutyric acid brain |
| toxicity in normal organisms, 188–190        | metabolism, 157               |
| Fructose-1,6-diphosphatase,                   | Gamma-aminobutyric acid      |
| gluconegenic pathway, 99                      | inborn error, 156–161         |
| Fructose-1,6-diphosphatase deficiency, 32     | Gamma-aminobutyric acid      |
| glycerol-1-phosphate, 106                     | transaminase deficiency, 159–160|
| hypoketonaemia, 106                           | Gastric lipase, 81, 91, 92    |
| lactic aciduria, 98–99                       | Gaucher’s disease, 280        |
| Fructose metabolism                          | displacement bone             |
| alternative pathways, 185                    | marrow transplantation, 236   |
| enzymes, 183–185                              | Fumarase, 98                  |
| liver pathway, 184                            | Fumaric aciduria, 98          |
| Fructose tolerance test, 182, 183             | Fumarylacetocoeacetase       |
| Fucosidosis, displacement bone               | deficiency, 102, 103, 107     |
| marrow transplantation, 236                   | G                                |
| Galactitol, 173, 177                          | Galactose                     |
| Galactosamine, 179                            | Galactose                     |
| intestinal mucosa                            | Galactose-1-phosphate         |
| absorption, 198–199                           | glucosyltransferase, 169      |
| malabsorption, 198–199                        | Galactose-1-phosphate uridylyl|
| metabolism, 171                               | transferase                   |
| small intestine, 197–199                      | Galactosemia, 169–176         |
| Galactose-1-phosphate, pregnancy, 177         | bilirubin, 180                |
| Galactose-1-phosphate uridylyl                | biochemistry, 171–173         |
| transferase, 169                              | bone marrow transplant, 179   |
| Galactosemia, 169–176                         | classical, 169                |
| Glucose                                       | hereditary fructose intolerance, 194–195 |
| clinical aspects, 169–171, 180                | intestinal mucosa, 198–199    |
| diagnosis, 176, 180                           | small intestine, 197–199      |
| international prospective study, 178         | tubular reabsorption, 204     |
| legumes, 175                                  | Glucose-6-phosphatase         |
| liver transplantation, 256                    | deficiency, 79–80             |
| long-term outcome, 169–171                    | Glucose carrier, genetic      |
| milk, 175                                     | control, 201                  |
| neurological degeneration, 171                |                                  |
| pathogenesis, 173–174                         |                                  |
| pseudotumor cerebri, 171                     |                                  |
| pulses, 175                                   |                                  |
| treatment, 175                                |                                  |
| Gamma-aminobutyric acid brain metabolism, 157|                                  |
| Gamma-aminobutyric acid metabolism inborn    |                                  |
| error, 156–161                                |                                  |
| Gamma-aminobutyric acid transaminase          |                                  |
| deficiency, 159–160                           |                                  |
| Gastric lipase, 81, 91, 92                    |                                  |
| Gaucher’s disease, displacement bone          |                                  |
| marrow transplantation, 234–235               |                                  |
| Gene therapy, 275–279                         |                                  |
| bone marrow, 276                              |                                  |
| central nervous system disease, 276           |                                  |
| cystic fibrosis, 278                          |                                  |
| disease models, 277                           |                                  |
| Duchenne muscular dystrophy, 278, 280         |                                  |
| dystrophin gene, 278                          |                                  |
| gene stability, 280                           |                                  |
| hepatocyte, 276                               |                                  |
| herpes simplex virus type 1, 277              |                                  |
| hypercholesterolemia, 277                     |                                  |
| skin, 276                                     |                                  |
| target organs, 280                            |                                  |
| tumor infiltrating lymphocyte, 279            |                                  |
| Genetic anemia, displacement bone            |                                  |
| marrow transplantation, 230–231               |                                  |
| Gluconegenic pathway                          |                                  |
| fructose-1,6-diphosphatase, 99                |                                  |
| glycerol, 99                                  |                                  |
| pyruvate, 99                                  |                                  |
| Glucose                                       |                                  |
| hereditary fructose intolerance, 194–195      |                                  |
| intestinal mucosa, 198–199                    |                                  |
| small intestine, 197–199                      |                                  |
| tubular reabsorption, 204                     |                                  |
| Glucose-6-phosphatase deficiency, 79–80       |                                  |
| Glucose carrier, genetic control, 201         |                                  |
|                                  |                                  |
Glucose-galactose carrier, 200–201, 205
Glutaric acid, fibroblast, 107
Glutaric acidemia type 1, 100
Glutaric aciduria type 1
  carnitine, 69–70
  urinary extraction, 95
Glutaryl-CoA dehydrogenase
deficiency, 100
d-Glyceric acidemia, 101
Glycerol, gluconeogenic pathway, 99
Glycerol-1-phosphate, fructose-1,6-
diphosphatase deficiency, 106
Glycerol-3-phosphate
  alcoholic cirrhosis, 106
  biliary atresia, 106
  hereditary fructose intolerance, 105–106
  liver, 105–106
  tyrosinemia type 1, 106
Glycerol kinase deficiency, 99
Glycine conjugate, stable isotope
dilution assay, 38
Glycogen storage disease, liver
  transplantation, 255
  incidence, 255
  natural history, 255
  transplantation candidates, 255
Glycogen storage disease type 1, 80
  liver transplantation, 267–268
  brain stem evoked response, 273
  infant, 273
Glycogen storage disease type 4, liver
  transplantation, 267–268
  brain stem evoked response, 273
  infant, 273
Glycogenosis, type 1, 80
Glycosuria, 204
GM1 gangliosidosis, displacement bone
  marrow transplantation, 238

H
Hemochromatosis, liver
  transplantation, 256
Hemophilia, liver transplantation, 258
Hepatic fructose transport system, 192
Hepatocyte, 207
  gene therapy, 276
Hepatocyte receptor, 208–209
Hepatocyte replacement, 209
Hepatoma, tyrosinemia, 108
Hereditary fructose intolerance,
  181–191
  aldolase B, 185
  clinical picture, 181–182
  diagnostic tests, 182, 183
  enzyme defect, 185–186
  fatty acid infiltration in liver, 194
  frequency, 181
  gastrointestinal discomfort, 187–188
  glucose, 194–195
  glycerol-3-phosphate, 105–106
  hepatic dysfunction, 187–188
  hypoglycemia, 195
  incidence, 195
  inheritance, 181
  liver steatosis, 194
  liver transplantation, 256
  pathophysiology, 186–188
  renal dysfunction, 187–188
  treatment, 190–191
Hereditary tyrosinemia type I, liver
  transplantation, natural history, 253
Herpes simplex virus type 1, gene
  therapy, 277
Hexadecanoate, beta-oxidation, 20–21
Hexose absorption, small intestine,
  197–199
Human gene therapy, 275–279
Human milk fat, medium chain fatty
  acid, 82–83
Hunter’s disease, displacement bone
  marrow transplantation, 237
Hurler’s disease, displacement bone
  marrow transplantation, 232–233, 246
Hydratase deficiency, 3-
  methylglutaconic, 107
L-3-Hydroxyacetyl-CoA dehydrogenase, 4
Hydroxybutyrate, 32, 161
  beta-Hydroxybutyrate, 8
  3-Hydroxybutyrate-acetoacetate ratio, 39
4-Hydroxybutyric aciduria, 100–101
  urinary extraction, 95
Hyperammonemia, 93
Hyperammonemia, 109–118
  carnitine, 117
  carrier detection, 120
  diagnosis, 109–113
  differential diagnosis, 111–113
  essential amino acid supplements, 114
exchange transfusion, 121-122
iatrogenic, 113
long-term treatment, 113-118
nitrogen excretion, 114-117
organic aciduria, 112
peritoneal dialysis, 121-122
premature newborn, 121
protein restriction, 114
routine tests, 111
Hyperammonemia coma, 113
Hypercholesterolemia, gene therapy, 277
Hyperinsulinemia, islet of Langerhans, 32
Hyperoxaluria type I, liver transplantation, 257-258
Hyperpyeocolic acidemia, 45
Hyperuricemia, fructose, 188
Hyperuricosuria, fructose, 188
Hypoglycemia. See also Ketotic hypoglycemia
hereditary fructose intolerance, 195
ketone body, 22
ketonemia, 22
carnitine, 24
clinical study methods, 23-24
fibroblast acyl-CoA dehydrogenase, 24, 29
insulin, 24
intermediary metabolites, 24
metabolic fuel, 24-27
metabolic relationship analysis, 23
plasma acylcarnitine, 27-28
plasma carnitine, 27-28
study methods, 23-29
urinary acylcarnitine, 24, 28-29
urinary dicarboxylic acid, 28
urinary organic acids, 24
ketonuria, 22
starvation provocation test, 31
terminology, 22
Hypoketonemia, 32
fructose-1,6-diphosphatase deficiency, 106

Intestinal mucosa
carbohydrate transfer, 197-202
fructose, 199
galactose, 198-199
glucose, 198-199
Islet of Langerhans, hyperinsulinemia, 32
L-Isoleucine, 137
Isoleucine metabolism, 139-140
Isomerase, 6
Isovaleric aciduria, 141
chronic progressive forms, 146-147
clinical presentation, 143-147
complications, 147
genetic counseling, 149
intermittent late onset form, 145-146
prognosis, 147-149
renal complications, 147
severe neonatal onset form, 143-145
skin disorders, 147
treatment, 147-149
Isovaleric acidemia, 57
carnitine, 63-66
Isovalerylcarnitine, 57, 141
Ito cell, 208

K
Ketone body, 8
free fatty acid, 32
hypoglycemia, 22
newborn, 38
Ketonemia, hypoglycemia, 22
carnitine, 24
clinical study methods, 23-24
fibroblast acyl-CoA dehydrogenase, 24, 29
insulin, 24
intermediary metabolites, 24
metabolic fuel, 24-27
metabolic relationship analysis, 23
plasma acylcarnitine, 27-28
plasma carnitine, 27-28
study methods, 23-29
urinary acylcarnitine, 24, 28-29
urinary dicarboxylic acid, 28
urinary organic acids, 24
Ketonuria, hypoglycemia, 22
Ketosis, associated disorders, 99-100
beta-Ketothiolase deficiency, carnitine, 68
3-Ketothiolase deficiency, carnitine, 64-66

I
I-cell disease, displacement bone marrow transplantation, 238
Immunophrophylaxis, displacement bone marrow transplantation, 225-227
Infant, fructose, 193
Ketotic hypoglycemia, 22
Krabbe's disease, displacement bone
marrow transplantation, 239
Kupffer cell, 208

L
Lactate biorate ratio, 39
Lactic acidosis, organic aciduria, 151
Lactic aciduria, fructose-1,6-
diphosphatase deficiency, 98–99
Lauric acid, 81
Leigh's syndrome, apparent life-
threatening event, 72–73
Lesch-Nyhan syndrome, displacement
bone marrow transplantation, 238

l-Leucine, 137
Leucine metabolism, 137–139
Lingual lipase, 81, 91, 92
Linoleic acid, 6
Linoleyl-CoA, beta-oxidation, 7
Lipolysis, fasting, 21
Lipoprotein lipase, 91, 92
Liver
acetyl-CoA, routes of disposal, 21
acylcarnitine, 63
alpha-oxidation, 16
cholesterol, 10, 11
fed state, 12
fructose intake, 194
glycerol-3-phosphate, 105–106
starved state, 12
Liver metabolism inborn error,
207–210
Liver steatosis, hereditary fructose
intolerance, 194
Liver transplantation, 213–219
alpha-1-antitrypsin deficiency, 213
transplantation candidates, 251
alpha-1-antitrypsin deficiency,
213–216, 265–266, 269
albuminuria, 220
clinical features, 213–214
fulminant form, 220
hematuria, 220
incidence, 249
long-term effects, 251
natural history, 250
pathogenesis, 214
results, 215–216
Byler disease, 268–269, 270
Crigler-Najjar syndrome
bilirubin, 221
brain damage, 221
heme synthesis inhibitor, 221
Crigler-Najjar syndrome type 1, 267,
269, 273–274
incidence, 257
long-term effects, 257
natural history, 257
transplantation candidates, 257
cystic fibrosis, 219
cystinosis, 262
familial hypercholesterolemia, 257,
270
galactosemia, 256
genetic disorders, 256
glycogen storage disease, 255
glycogen storage disease type 1,
267–268, 273
infant, 273
glycogen storage disease type 4,
267–268, 273
hemochromatosis, 256
hemophilia, 258
hereditary fructose intolerance, 256
hereditary tyrosinemia type 1, 218
incidence, 253
long-term effects, 254
natural history, 253
transplantation candidate, 253–254
hyperoxaluria type I, 257–258
indications, 261, 263–271
metabolic diseases with liver
damage, 249–256
metabolic diseases without liver
damage, 256–258
nul-gene defect, 260
orthotopic, 209–210
primary hyperoxaluria type I,
218–219
propionic aciduria, 261
protein C deficiency, 258
protoporphyria, 255–256
timing, 263–271
tyrosinemia, 108, 260–261, 268, 270
Wilson's disease, 216–218, 261–262,
266–267, 270
ZZ phenotype, 260
Long chain acyl-CoA synthesis, l
Long chain acyl-CoA synthetase
cytosol, 23
peroxisome, 23
Long chain dicarboxylic fatty acid, beta-oxidation, 1
Long chain fatty acid beta-oxidation, 1
mitochondria, 2–3
Lynen cycle of ketogenesis, 19

M
M/z 99 fragment, 60
Malonic aciduria, methylmalonic acid, 98
Maple syrup urine disease
branched-chain 2-oxo acid dehydrogenase, 140–141
chronic progressive form, 146–147
complications, 147
genetic counseling, 149
intermittent late onset form, 145–146
prognosis, 147–149, 152
severe neonatal onset form, 143–145
Maroteaux Lamy syndrome,
displacement bone marrow transplantation, 237
Maternal phenylketonuria, 125–135
MCT
drawbacks, 90
dumping syndrome, 90
fat absorption, newborn, 86
MCT oil, absorption, 86–89
Medium chain CoA dehydrogenase, 57
 carnitine, 58, 64–66
frequency, 79
sudden infant death syndrome, 78
Medium chain dicarboxylic fatty acid, beta-oxidation, 1
Medium chain fatty acid absorption, newborn gastric mucosa, 84–86
beta-oxidation, 1
characteristics, 87
human milk fat, 82–83
maternal diet, 83
metabolism, 81
triglyceride, newborn stomach, 83, 85
Medium chain organic acid, conjugation mechanisms, 103
Medium chain triglyceride, 81–89
metabolism, 82
Menkes’ syndrome, apparent life-threatening event, 73
Mental retardation, phenylketonuria, 125
Metabolic abnormality
apparent life-threatening event, 72–74
retrospective analysis, 72–74
sudden infant death syndrome, 74–76
Metachromatic leukodystrophy, displacement bone marrow transplantation, 235
5,10-Methylene tetrahydrofolate reductase deficiency, 57–66
3-Methylglutaconic aciduria, cholesterol synthesis, 107
3-Methylglutaconic aciduria type I, 95–97
3-Methylglutaconic aciduria type II, 95–97
urinary extraction, 95
Methylmalonic acid, malonic aciduria, 98
Methylmalonic acidemia, 93, 142
chronic progressive forms, 146–147
clinical presentation, 143–147
complications, 147
dehydration, 153
genetic counseling, 149
intermittent late onset form, 145–146
odd-chain fatty acid, 152
prognosis, 147–149, 151–152
renal complications, 147
severe neonatal onset form, 143–145
skin disorders, 147
treatment, 147–149
Methylmalonic aciduria, carnitine, 63–66
(Methyl)malonic semialdehyde dehydrogenase deficiency, 97
Methylmalonyl carnitine, 60
Mevalonic aciduria, 97
Microcephaly, phenylketonuria, 133
Migration inhibitory factor, 223
Milk, galactosemia, 175
Mitochondria
beta-oxidation, 1, 3–8
blood platelets, 36–37
control, 20–21
episodic hypoglycemia, 19
flavoprotein-linked dehydrogenation, 19
hydration, 19
inherited disorders, 19–34
Mitochondria, beta-oxidation (contd.)
leukocytes, 36–37
lipid storage myopathy, 19
NAD⁺-linked dehydrogenation, 19
polyunsaturated long chain fatty
cacid oral loading test, 37
radiochemical measurement, 37
radiolabeled fatty acid, 37
rate of recycling of CoA, 20–21
redox state, 20–21
Reye's syndrome, 19
role, 9–10
saturated acyl-CoA ester, 19
suberylglycinuria, 19
thiolysis, 19
dicarboxylic fatty acid oxidation, 9
fatty acid, 1–3
fatty acid oxidation
liver, 12
regulation, 12–13
long chain fatty acid, 2–3
peroxisome, 2–3
Mitochondria myopathy, 76
Mitochondrial long chain fatty acid
oxidation, extrahepatic tissues, 12–13
Mitochondrial protein, peptide leader, 39
Modified defective virus, 275
Monocyte, 16
Monocyte stimulating factor, 16
Monosaccharide intolerance,
secondary, 199
Morquio's disease, displacement bone
marrow transplantation, 237
Mucopolysaccharidosis, displacement
bone marrow transplantation, 232
Multiple acyl-CoA dehydrogenase
deficiency, 57
carnitine, 64–66
valproate, 68
Muscle, peroxisomal fatty acid
oxidation, 17
Myogenic hypotonia, carnitine, 68–69
Newborn, ketone body, 38
Niemann-Pick disease, displacement
bone marrow transplantation, 236, 238–239
Ninhydrin, 93
Non-sex-linked severe combined
immune deficiency,
displacement bone marrow
transplantation, 228
Nonfunctional lymphocyte,
displacement bone marrow
transplantation, 229–230
Nonketotic hyperglycinemia, 155–156,
166
biochemical defect, 156
clinical picture, 155–156
strychnine, 166
treatment, 156
Noradrenaline, 165
Nucleic acid synthesis, orotic aciduria,
120
Nul-gene defect, liver transplantation,
260
O
Octanoate, sudden infant death
syndrome, 78
Odd-carbon number fatty acid, 143
Odd-chain fatty acid
methylmalonic acidemia, 152
propionic acidemia, 152
propionyl-CoA, 151
Oleate oxidation, 9
Oleic acid, 51
Oleoyl-CoA, beta-oxidation, 7
Organic acid, conjugation, 102–104
Organic acidemia, carnitine, urinary
excretion, 104
Organic aciduria, 57–66, 93–104
analytical chemical aspects, 93–95
catabolism defects, 93
derivatized, 94
diethyl ether, 94
ethyl acetate, 94
gas chromatography-mass
spectrometry, 93
hyperammonemia, 112
lactic acidosis, 151
quadrupole instrument, 95
solvent extraction, 94
urinary excretion, 94–95
Organogenesis, 126

N
NAD⁺-linked dehydrogenation, 19
Neonatal adrenoleukodystrophy, 45
Neurotransmitter, phenylalanine, 133
Neurotransmitter catabolism, 166
Neurotransmitter metabolism genetic
disease, 155–163
SUBJECT INDEX

Orotic aciduria, nucleic acid synthesis, 120
Orthotopic liver transplantation, 209–210
Osteopetrosis, displacement bone marrow transplantation, 231–232
Osteosarcoma cell, 280–281
2-Oxobutyrate metabolism defect, 101

P
Palmitate oxidation, 9
Palmitoyl-CoA, triple-quadrupole mass spectrometric detection, 40
Pancreatic lipase, 81
Pancreatin, 133
Pathogenic urinary metabolite, fasting, 22
Peripheral decarboxylase inhibitor, 167
Peritoneal dialysis, hyperammonemia, 121–122
Peroxisomal 3-oxoacyl-CoA thioloase deficiency, 48
Peroxisomal fatty acid oxidation, muscle, 17
Peroxisome
beta-oxidation, 1, 3–8, 4–5, 8
chain-shortening system, 8
dihydroxycholestanic acid, 44
disorders, 43–51
inborn error biochemical characteristics, 49
inborn error diagnosis, 49
inborn errors, 44–49
pathogenic aspects, 50–51
peroxisome deficiency disorder, 44–46
plant, 16
prenatal diagnosis, 50
role, 9–10
treatment, 51
trihydroxycholestanic acid, 44
unidentified disorders, 48–49
very long chain fatty acids, 43–44
dicarboxylic fatty acid oxidation, 9
fatty acid, 1–3
fatty acid oxidation
liver, 12
regulation, 12–13
long chain acyl-CoA synthetase, 23
mitochondria, 2–3
short chain fatty acid oxidation, 15
very long chain fatty acid, 9
Peroxisome deficiency disorder, 44–46
Peroxisome induction, 13
Phagocyte error, displacement bone marrow transplantation, 230
Phenylalanine
congenital heart damage, 132
neurotransmitter, 133
safe limit, 134
Phenylalanine ammonia-lyase, 133
Phenylketonuria
congenital heart disease, 125
dietary control in first trimester, 130
embryonic development, 126–127
fetal damage, 125–135
fetus, 126–129
amino acid supplementation, 128
amino transport, 128
brain development, 127
damage mechanisms, 127–129
dopamine, 128
phenylalanine, 127
serotonin, 128
low birth weight, 125
mental retardation, 125
microcephaly, 125, 133
phenylalanine-restricted, 129
spontaneous abortion, 125
strict dietetic management, 134
terminology, 133
treatment, 129
treatment outcome, 129–131
Phenylpropionate loading, 38
Phenylpropionate loading test, 39
Phytytic acid, oxidation, 10–12, 16
Phytic acid oxidation, 15
Refsum disease, 16
Pig pancreatin, 133
Placental transport, amino acid, 125–126
Plant, beta-oxidation, 16
Plasma, acid-base changes, 93
Polyethylene glycol-modified enzyme, 134
Polyol, 173
Polyunsaturated fatty acid partial hydrogenation, 6
trans double bond, 6
Pompe’s disease, displacement bone marrow transplantation, 238
Pregnancy, galactose-1-phosphate, 177
Premature newborn, hyperammonemia, 121
Primary hyperoxaluria type I, liver transplantation, 218–219
Propionic acidemia, 57, 141–142
  carnitine, 63–66
  chronic progressive forms, 146–147
  clinical presentation, 143–147
  complications, 147
  dehydration, 153
genetic counseling, 149
  intermittent late onset form, 145–146
  odd-chain fatty acid, 152
  prognosis, 147–149
renal complications, 147
severe neonatal onset form, 143–145
skin disorders, 147
treatment, 147–149
Propionic aciduria
  late onset, 152
  liver transplantation, 261
Propionyl-CoA, 92
  metabolic disturbances, 143
  odd-chain fatty acid, 151
Propionyl-CoA pathway, 139–140
Propionylcarnitine, 57
Prostaglandin, beta-oxidation, 1, 10
Protein C deficiency, liver transplantation, 258
Protoporphyrin, liver transplantation, 255–256
Pseudo-Zellweger syndrome, 48
Pseudoneonatal adrenoleukodystrophy, 48
Pseudotumor cerebri, galactosemia, 171
Purine catabolism, liver pathways, 189
Pyridoxine, 158–159
Pyridoxine-responsive convulsion, 156–159
  biochemical defect, 158
  clinical picture, 158
  treatment, 158–159
Pyruvate, gluconeogenic pathway, 99
Retrovirus vector, 275
Reye's syndrome, 112–113
  apparent life-threatening event, 73
dienoyl-CoA reductase, 17
epidemiological study, 17
valproate, 68
S
San Filippo A disease, displacement bone marrow transplantation, 237
San Filippo B disease, displacement bone marrow transplantation, 233–234
Saturated acyl-CoA ester, 19
Saturated dicarboxylic acid, 39
Secondary monosaccharide intolerance, 199
Selenium, 135
Severe combined immune deficiency, displacement bone marrow transplantation, 228
cartilage hair dysplasia, 228
Short chain fatty acid, beta-oxidation, 1
Short chain fatty acid oxidation, peroxisome, 15
Short chain organic acid, conjugation mechanisms, 103
Shortened acyl-CoA, 8
Skin, gene therapy, 276
Small intestine
  fructose, 197–199
galactose, 197–199
  glucose, 197–199
  hexose absorption, 197–199
Sodium benzoate, 121
Solvent extraction, organic aciduria, 94
Sorbitol, 190
Starvation provocation test, hypoglycemia, 31
Strychnine, nonketotic hyperglycinemia, 166
Succinic aciduria, 98
Succinic semialdehyde dehydrogenase deficiency, 161
  biochemical defect, 161
  clinical picture, 161
  treatment, 161
Succinyl-CoA:3-ketoacid CoA-transferase, 99
Succinylacetone excretion, 108
Sucrose, 190
Sudden infant death syndrome, 71–77
dehydrogenase
acylcoenzyme A deficiency, 72
age of death, 79
apparent life-threatening event, 71
carnitine, 78
definition, 71
fasting, 72
floppy baby, 75, 76
gastrointestinal infection, 72
investigation protocol, 78
medium chain CoA dehydrogenase, 78
metabolic abnormality, 72, 74–76
octanoate, 78
postmortem, 71
sibling screening, 38–39

Tyrosinemia type 1, 102, 103
glycerol-3-phosphate, 106
Tyrosinemia type I, urinary extraction, 95

U
Unsaturated dicarboxylic acid, 39
Unsaturated fatty acid
cis double bond, 6
oxidation, 6
Uracil catabolism, 97
Urea cycle, 110
Urea cycle inborn error, 109–118
carnitine, 117
carrier detection, 120
diagnosis, 109–113
differential diagnosis, 111–113
essential amino acid supplements, 114
long-term treatment, 113–118
nitrogen excretion, 114–117
prenatal diagnosis, 120
protein restriction, 114
routine tests, 111
Urinary glycerol, 99

V
L-Valine, 137
Valine catabolism, 97
Valine metabolism, 139–140
Valproate
medium chain CoA dehydrogenase, 68
multiple acyl-CoA dehydrogenase
deficiency, 68
Reye’s syndrome, 68
Very long chain fatty acid
beta-oxidation, 1
increased level, 53
peroxisome, 9

W
West’s syndrome, apparent life-threatening event, 73
Wilson’s disease
ceruloplasmin, 221
hepatic prognosis, 217
liver transplantation, 216–218,
261–262, 266–267, 270
Wilson's disease, liver transplantation (contd.)
   incidence, 252
   long-term results, 253
   natural history, 252
   transplantation candidates, 252
   symptomatic liver involvement, 216
   symptoms, 216
Wiskott-Aldrich syndrome,
   displacement bone marrow transplantation, 229
Wolman's disease, displacement bone marrow transplantation, 236, 246

X
   X-linked adrenoleukodystrophy, 46, 47
   Xenobiotic
      beta-oxidation, 1
      carboxy side chain, 10
      oxidation, 10

Z
   Zellweger-like syndrome, 46, 47
   Zellweger syndrome, 45
   ZZ phenotype, liver transplantation, 260